Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Edward Clayton is active.

Publication


Featured researches published by Edward Clayton.


Xenobiotica | 1998

19F-NMR and directly coupled HPLC-NMR-MS investigations into the metabolism of 2-bromo-4-trifluoromethylaniline in rat : a urinary excretion balance study without the use of radiolabelling

Graeme B. Scarfe; B. Wright; Edward Clayton; S. Taylor; Ian D. Wilson; John C. Lindon; J. K. Nicholson

1. The metabolic fate and urinary excretion of 2-bromo-4-trifluoromethylaniline has been studied in rat using 19F-NMR spectroscopic and directly coupled HPLC-NMR-MS methods. The compound was dosed to Sprague-Dawley rats (50 mg kg-1, i.p.) and urine collected over 0-8, 8-24 and 24-48 h post-dosing. 2. A total urinary recovery of 53.5 +/- 7.0% of the dose was achieved up to 48 h after dosing. The major metabolite in the urine was identified as 2-amino-3-bromo-5-trifluoromethylphenylsulphate accounting for a total of 35.7 +/- 6.2% of the dose. 3. Further metabolites detected were 2-bromo-4-trifluoromethylphenylhydroxylamine-1V-glucuronide (9.7 +/- 0.2% of the dose), 2-bromo-4-trifluoromethylaniline-N-glucuronide (3.0 +/- 0.3%) and 2-amino-3-bromo-5-trifluoromethylphenylglucuronide (2-St 0-4). Minor metabolites, including 2-bromo-4-trifluoromethylphenylhydroxylamine-O-glucuronide, 2-amino-3-bromo-5-trifluoromethylphenol and 2-bromo-4-trifluoromethylphenylsulphamate, in total accounted for 2.3 +/- 0.9% of the dose. 4. Directly coupled HPLC-NMR-MS and 19F-NMR spectroscopy proved to be efficient techniques for the unequivocal and rapid determination of the urinary metabolic fate and excretion balance of fluorinated xenobiotics without the need for radiolabelling.


Xenobiotica | 1999

Quantitative studies on the urinary metabolic fate of 2-chloro-4-trifluoromethylaniline in the rat using 19F-NMR spectroscopy and directly coupled HPLC-NMR-MS

Graeme B. Scarfe; B. Wright; Edward Clayton; S. Taylor; Ian D. Wilson; John C. Lindon; J. K. Nicholson

1. The metabolism and urinary excretion of 2-chloro-4-trifluoromethylaniline has been studied in the rat using 19F-NMR spectroscopy and directly coupled HPLC-NMR-MS methods. The compound was dosed to three male Sprague-Dawley rats (50 mg kg(-1) i.p.) and urine collected over 0-8, 8-24 and 24-48 h post-dosing. 2. A total urinary recovery of 56.3+/-2.2% of the dose was achieved up to 48 h after dosing. The major metabolite in the urine was identified as 2-amino-3-chloro-5-trifluoromethylphenylsulphate accounting for a total of 33.5+/-2.2% of the dose. 3. Further metabolites detected and characterized included 2-chloro-4-trifluoromethylphenylhydroxylamine glucuronide (13.2+/-0.5% of the dose), 2-amino-3-chloro-5-trifluoromethylphenylglucuronide (3.8+/-0.4% of the dose) and 2-chloro-4-trifluoromethylaniline-N-glucuronide (3.6+/-0.1% of the dose). Several minor metabolites were also found and identified, including 2-chloro-4-trifluoromethylphenylsulphamate, which together accounted for 2.1+/-0.4% of the dose. 4. Directly coupled HPLC-NMR-MS and 19F-NMR spectroscopy is shown to provide an efficient approach for the unequivocal and rapid determination of the quantitative urinary metabolic fate and excretion balance of a fluorinated xenobiotic without the necessity for specific radiolabelling.


Xenobiotica | 2002

Identification of the urinary metabolites of 4-bromoaniline and 4-bromo-[carbonyl-13C]-acetanilide in rat.

Graeme B. Scarfe; J. K. Nicholson; John C. Lindon; Ian D. Wilson; S. Taylor; Edward Clayton; B. Wright

1. The urinary excretion of 4-bromoaniline and its [carbonyl-13C]-labelled N-acetanilide, together with their corresponding metabolites, have been investigated in the rat following i.p. administration at 50 mg kg−1. 2. Metabolite profiling was performed by reversed-phase HPLC with UV detection, whilst identification was performed using a combination of enzymic hydrolysis and directly coupled HPLC-NMR-MS analysis. The urinary metabolite profile was quantitatively and qualitatively similar for both compounds with little of either excreted unchanged. 3. The major metabolite present in urine was 2-amino-5-bromophenylsulphate, but, in addition, a number of metabolites with modification of the N -acetyl moiety were identified (from both the [13C]-acetanilide or produced following acetylation of the free bromoaniline). 4. For 4-bromoacetanilide, N-deacetylation was a major route of metabolism, but despite the detection of the acetanilide following the administration of the free aniline, there was no evidence of reacetylation (futile deacetylation). 5. Metabolites resulting from the oxidation of the acetyl group included a novel glucuronide of an N-glycolanilide, an unusual N-oxanilic acid and a novel N-acetyl cysteine conjugate.


Journal of Chromatography B: Biomedical Sciences and Applications | 2000

Identification and quantification of metabolites of 2,3,5,6-tetrafluoro-4-trifluoromethylaniline in rat urine using 19F nuclear magnetic resonance spectroscopy, high-performance liquid chromatography–nuclear magnetic resonance spectroscopy and high-performance liquid chromatography–mass spectrometry

Graeme B. Scarfe; Edward Clayton; Ian D. Wilson; Jeremy K. Nicholson

The urinary excretion profile and identity of the metabolites of 2,3,5,6-tetrafluoro-4-triflouromethylaniline, following i.p. administration to the rat at 50 mg kg(-1), were determined using a combination of 19F-NMR, HPLC-NMR and HPLC-MS. A total of 38% of the dose was eliminated in the urine as five metabolites. The major routes of metabolism were N-glucuronidation, sulfation and oxidation with a significant amount of metabolic defluorination to give a number of ortho-ring hydroxylated metabolites. The oxidised metabolites were excreted as glucuronide and/or sulfate conjugates.


Archive | 1997

Quinazoline derivatives and pharmaceutical compositions containing them

Andrew Peter Thomas; Craig Johnstone; Edward Clayton; Elaine Sophie Elizabeth Stokes; Jean-Jacques Marcel Lohmann; Laurent Francois Andre Hennequin


Archive | 2007

QUINAZOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE PRODUCTION OF AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT

Peter Thomas Andrew; Craig Johnstone; Edward Clayton; Elizabeth Stokes Elaine Sophie; Marcel Lohmann Jean-Jacques; Andre Hennequin Laurent Francois


Archive | 2005

COMPUESTOS DERIVADOS DE 4-(ANILINO SUSTITUIDO)-QUINAZOLINA; PROCESO DE PREPARACION; COMPOSICION FARMACEUTICA; Y USO DEL COMPUESTO EN EL TRATAMIENTO DE ANGIOGENESIS Y/O REDUCCION DE LA PERMEABILIDAD VASCULAR.

Andrew Peter Thomas; Laurent Francois Andre Hennequin; Craig Johnstone; Elaine Sophie Elizabeth Stokes; Jean-Jacques Marcel Lohmann; Edward Clayton


Archive | 1997

Chinazolin derivate und diese enthaltende pharmazeutische zusammenstellungen

Andrew Peter Thomas; Laurent Francois Andre Hennequin; Craig Johnstone; Elaine Sophie Elizabeth Stokes; Jean-Jacques Marcel Lohmann; Edward Clayton


Archive | 1997

Chinazolin derivate und diese enthaltende pharmazeutische zusammenstellungen Quinazoline derivatives and those containing pharmaceutical assortments

Edward Clayton; Laurent Francois Andre Hennequin; Craig Johnstone; Jean-Jacques Marcel Lohmann; Elaine Sophie Elizabeth Stokes; Andrew Peter Macclesfield Thomas


Archive | 1997

Quinazoline derivatives and to pharmaceutical compositions containing them

Andrew Peter Thomas; Laurent Francois A Z Hennequin; Craig Johnstone; Elaine Sophie Elizabeth Stokes; Jean-Jacques Marcel Lohmann; Edward Clayton

Collaboration


Dive into the Edward Clayton's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

B. Wright

Imperial College London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

S. Taylor

Imperial College London

View shared research outputs
Researchain Logo
Decentralizing Knowledge